Technology Listings


115 Results Sort By:
Targeted Anti-Cancer Nanoparticle Therapy
Application A drug-carrying nanoparticle that selectively targets cancer cells. Key Benefits Incorporates an already proven anti-cancer therapeutic. Increases deliverability. Targets cancer cells. Market Summary Tris DBA palladium has been shown to have anti-cancer activity against melanoma and pancreatic cancer. However, Tris DBA has not...
Published: 9/9/2019       Inventor(s): Jack Arbiser, Lily Yang
Beta Blocker Isomers as Angiogenesis Inhibitors
Application β-blocker inactive form of propranolol for treatment of angiogenic disease. Key Benefits Reduced side-effects, such as low blood pressure and low blood sugar. Increased anti-angiogenic activity compared to the active isoform. Market Summary Angiogenesis is the growth of blood vessels from the existing vasculature. While it...
Published: 7/29/2019       Inventor(s): Jack Arbiser
ADGRB3/BAI3 Knockout Mouse
ApplicationKnockout mouse models for adhesion G protein-coupled receptors B3, brain-specific angiogenesis inhibitor-3 (ADGRB3/BAI3) gene study.Technical SummaryEmory University researchers have developed a knockout mouse model for the ADGRB3/BAI3 gene. Mice were generated by CRISP/cas9 technology on C57Bl6 background. These mice can be used to stud...
Published: 7/9/2019       Inventor(s): Erwin Van Meir
ADGRB1/BAI1 Knockout Mouse
ApplicationKnockout mouse models for adhesion G protein-coupled receptors B1, brain-specific angiogenesis inhibitor-1 (ADGRB1/BAI1) gene study.Technical SummaryEmory University researchers have developed a knockout mouse model for the ADGRB1/BAI1 gene. These mice were developed through homologous recombination and have LacZ gene knock-in. Mice were...
Published: 7/9/2019       Inventor(s): Erwin Van Meir
Biomarker for Clinical Prognosis for Lung Cancer Patients
Application Biomarker to predicting clinical outcome and treatment options for lung cancer patients. Key Benefits Provides early determination of prognosis. Market Summary Upon diagnosis with cancer, there are many different treatment options. While some more aggressive treatment options can be more dangerous to the patient, these aggressiv...
Published: 7/2/2019       Inventor(s): Adam Marcus, Brian Pedro, Jessica Konen
Small Molecule Inhibitors of Mcl-1 as Anti-Cancer Agent
ApplicationMyeloid cell leukemia 1 (Mcl-1) inhibitor to enhance DNA replication stress sensitivity for cancer therapy.Key BenefitsInhibits DNA repair in cancer cells.Used in combination with existing cancer therapy.Market SummaryChemoresistance occurs when cancer cells develop resistance to chemotherapy drugs, and appearance of chemoresistance grea...
Published: 6/24/2019       Inventor(s): Xingming Deng, Guo Chen, Abu Syed Md Anisuzzaman
Combination Therapy for Increasing Venetoclax Sensitivity in Multiple Myeloma
Application Marker and co-therapy that inhibits succinate dehydrogenase to increase patient response to venetoclax. Key Benefits Co-therapy increases MM sensitivity to venetoclax treatment. Identifies patients who will respond to venetoclax therapy. Market Summary Multiple Myeloma (MM) is a cancer of plasma cells responsible for making ant...
Published: 6/18/2019       Inventor(s): Malathy (mala) Shanmugam, Richa Bajpai
Small Molecule Inhibitors of NADPH Oxidase 4 (NOX4) Signaling
ApplicationSmall molecule inhibitors of NOX4 signaling with a wide array of therapeutic potential.Key BenefitsSmall molecule inhibitors of NOX4 signaling.Low cytotoxicity.Market SummaryThe NADPH oxidase 4 (NOX4) has gained considerable and growing attention during the past years because of its potential key involvement in a variety of diseases, som...
Published: 5/13/2019       Inventor(s): Bernard Lassegue, Kathy Griendling, David Brown, Qian Xu, Osman Guner, J. Phillip Bowen, Amol Kulkarni, E. Blake Watkins
Reovirus Treatment of Triple-Negative Breast Cancer
Application Therapeutic oncolytic reovirus for treatment of triple-negative breast cancer. Key Benefits Specific for Triple-Negative Breast cancer. Can be a good candidate for combination therapy. Market Summary Triple-negative breast cancer (TNBC) constitutes approximately 15% of all breast cancer, has a higher rate of relapse, and shorte...
Published: 5/9/2019       Inventor(s): Bernardo Mainou, Roxana Rodriguez, Angela Berger
Glycolysis Inhibitors as Potential Cancer Therapeutics
ApplicationA new potential anti-cancer agent that inhibits the glycolytic enzyme PGAM1 and thereby tumor growth.Key BenefitsTargets tumor metabolism by inhibiting glycolytic enzyme and turning off tumor metabolism.Inhibition of glycolytic enzyme (PGAM1) by these inhibitors leads to significant reduction in tumor growth.Market SummaryTreating cancer...
Published: 4/23/2019       Inventor(s): Jing Chen, Taro Hitosugi, Sumin Kang
1 2 3 4 5 6 7 8 9 10 ...